Bondronat


Also found in: Wikipedia.

Bondronat

A brand name for IBANDRONIC ACID.
References in periodicals archive ?
First registered and used in the clinic under the trade name of Bondronat in Germany and Austria in 1996, sodium ibandronate was approved by the FDA to come into the market as a daily treatment of osteoporosis under the trade name of Boniva.
The assessment affects nineteen centrally authorised medicines as well as various medicines that have been nationally authorised: Avastin, Bondenza, Bondronat, Bonviva, Cellcept, Fuzeon, Herceptin, Invirase, Mabthera, Mircera, Neorecormon, Pegasys, Roactemra, Tamiflu, Tarceva, Viracept, Xeloda, Xenical and Zelboraf.
Recently announced data show that Bondronat (ibandronic acid) administered for the treatment of metastatic bone disease for 15 minutes has a safety profile consistent with the same dose of the drug administered during an hour.
Bondronat, made by Roche, is used to treat breast cancer which has spread to the bone -also known as metastatic bone disease.
The arrival of Bondronat, made by Roche, was welcomed by campaigners and doctors.
Bondronat can be taken as a pill, so patients can manage treatment without going into hospital.
Among the most promising prospects are CERA (Continuous Erythropoiesis Receptor Activator) for anemia, Bondronat for osteoporosis, the still-unnamed R450 for stress urinary incontinence (most common in women) and MRA for rheumatoid arthritis.
Approaching patent expiries for Bondronat and Zometa and the subsequent availability of cheaper generic versions may raise the barrier to uptake of more novel but costly emerging agents such as denosumab.
In addition to these anti-cancer agents, the Roche oncology portfolio includes a comprehensive collection of medicines that can help improve the quality of life of cancer patients: Bondronat (for prevention of skeletal events in patients with breast cancer and bone metastases, hypercalcaemia of malignancy), Kytril (for chemotherapy and radiotherapy-induced nausea and vomiting), Neupogen (for cancer-related neutropenia), and NeoRecormon (for anaemia in various cancer settings).
The Roche oncology portfolio also includes NeoRecormon (anaemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcaemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (hairy cell and chronic myeloid leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).
Other key products include NeoRecormon (anaemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).
The Roche oncology portfolio also includes NeoRecormon (anemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (hairy cell and chronic myeloid leukemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).